Cell MedX (Cell MedX) Interest Expense : $-0.07 Mil (TTM As of Feb. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Cell MedX Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cell MedX's interest expense for the three months ended in Feb. 2024 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.07 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cell MedX's Operating Income for the three months ended in Feb. 2024 was $ -0.06 Mil. Cell MedX's Interest Expense for the three months ended in Feb. 2024 was $ -0.01 Mil. Cell MedX did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cell MedX Interest Expense Historical Data

The historical data trend for Cell MedX's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell MedX Interest Expense Chart

Cell MedX Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Interest Expense

Get a 7-Day Free Trial

-0.02

-0.03

-0.05

Cell MedX Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.02	-0.03	-0.02	-0.01

Cell MedX Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07 Mil.

Cell MedX (OTCPK:CMXC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cell MedX's Interest Expense for the three months ended in Feb. 2024 was $-0.01 Mil. Its Operating Income for the three months ended in Feb. 2024 was $-0.06 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Feb. 2024 was $0.00 Mil.

Cell MedX's Interest Coverage for the quarter that ended in Feb. 2024 is calculated as

Cell MedX did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Cell MedX (Cell MedX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cell MedX Corp (OTCPK:CMXC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

123 W. Nye Lane, Suite 446, Carson City, NV, USA, 89706

Website

https://www.cellmedx.com

Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications. The company's product portfolio consists of electromedical technologies, ebalance, and others.

Executives

Richard Jeffs	10 percent owner	FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz	director, officer: Chief Executive Officer	SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves	10 percent owner	904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty	director, officer: CEO, CFO, Treas., Sec	4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta	director, officer: COO	#810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams	director	7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen	director, officer: CEO	635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson	officer: Chief Medical Officer	9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina	officer: CFO, Treasurer and Secretary	789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett	10 percent owner	121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer	director, officer: Chief Technology Officer	C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103

Cell MedX (Cell MedX) Headlines

From GuruFocus

Cell MedX Insider Buys 22,500 Shares

By Kyle Ferguson Kyle Ferguson • 11-11-2016